NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 27 min 17 sec ago

T2 Translational Research: Research Leading to New Health Care Practices, Community Programs and Policies Affecting Older Persons (R21 Clinical Trial Optional)

Fri, 2017-11-17 10:15
Funding Opportunity PAR-18-178 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages exploratory/developmental research projects on translational research (T2) directed towards development of health care practices, community programs and policies, including monitoring and quality improvement for pharmacological and non-pharmacological approaches for preventing and treating key health issues affecting the elderly. For the purposes of this FOA, T2 translational research on aging is defined as research to gather information needed to develop or evaluate methods of translating results from clinical studies into everyday clinical practice and health decision making (e.g., adapting an efficacious intervention for application in clinical practice and evaluating its effectiveness in different clinical settings). Methods for T2 translational research include but are not limited to intervention studies, systematic reviews, meta-analysis, outcomes research and implementation research.

T1 Translational Research: Novel Interventions for Prevention and Treatment of Age-related Conditions (R21 Clinical Trial Optional)

Fri, 2017-11-17 10:12
Funding Opportunity PAR-18-177 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages exploratory/developmental research projects to accelerate the pace of development of novel therapeutics involving biologics, pharmacological and non-pharmacological approaches for preventing and treating key health issues affecting the elderly. For the purposes of this FOA, T1 translational research on aging is defined as the application of basic and clinical biomedical findings towards the development of new strategies for prevention and treatment of age-related pathologies.

Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional)

Fri, 2017-11-17 10:10
Funding Opportunity PAR-18-086 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is part of an NIH initiative known as Collaborative Research on Addiction at NIH (CRAN). Areas supported by this FOA include research to generate and conduct preliminary tests of targeted addiction treatment to address multiple substances, which may include alcohol, tobacco and other drug use (ATOD).

Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R33 Clinical Trial Optional)

Fri, 2017-11-17 10:08
Funding Opportunity PAR-18-085 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is part of an NIH initiative known as Collaborative Research on Addiction at NIH (CRAN). Areas supported by this FOA include research to generate and conduct preliminary tests of targeted addiction treatment to address multiple substances, which may include alcohol, tobacco and other drug use (ATOD).

Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional)

Fri, 2017-11-17 10:04
Funding Opportunity PAR-18-084 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange.

Limited Competition: Small Grant Program for NIDDK K01/K08/K23 Recipients (R03 Clinical Trial Optional)

Fri, 2017-11-17 09:55
Funding Opportunity PAR-18-103 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, and K23 recipients the opportunity to apply for Small Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.

Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)

Fri, 2017-11-17 09:53
Funding Opportunity PAR-18-102 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide support for New Investigators from backgrounds nationally underrepresented in biomedical and behavioral research to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The R21 is intended to support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate the transition to research independence of New Investigators from backgrounds underrepresented in the biomedical and behavioral sciences. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Optional)

Fri, 2017-11-17 09:52
Funding Opportunity PAR-18-083 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. This FOA is intended to support research education activities that enhance the knowledge of substance abuse and addiction research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/service providers, clinical researchers or optimally a combination of the two. This mechanism may not be used for support of non-research-related clinical training. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Research Experiences.

Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional)

Fri, 2017-11-17 09:50
Funding Opportunity PAR-18-082 from the NIH Guide for Grants and Contracts. This FOA will use an NIH Small Research Grant (R03) award mechanism and seeks to facilitate the entry of beginning investigators into the field of behavioral science research related to drug abuse. R03 projects will be supported for one year to allow gathering of pilot data with the intent that PDs/PIs become better positioned to seek additional support for independent research programs. To be appropriate for a B/Start award, research must be primarily focused on behavioral processes and research questions.

Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)

Fri, 2017-11-17 09:47
Funding Opportunity PAR-18-081 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.

NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

Fri, 2017-11-17 09:45
Funding Opportunity PAR-18-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

Limited Competition: RCMI Research Coordination Network (RRCN) (U54)

Fri, 2017-11-17 01:33
Funding Opportunity RFA-MD-18-001 from the NIH Guide for Grants and Contracts. The RCMI Research Coordination Network (RRCN), formerly known as the RCMI Translational Research Network (RTRN), was established in 2007 to enhance collaboration across RCMI institutions. The network is designed to engage all stakeholders in the RCMI institutions, increase the quality and efficiency of basic biomedical, behavioral, and clinical research, facilitate study participant recruitment and retention, and increase the efficiency of the implementation and dissemination of research advances to improved health outcomes among minority and health disparity populations. Maintaining the longstanding networking and collaboration with the RCMI grantee community is key to the continued success of this program.

Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33)

Thu, 2017-11-16 09:21
Funding Opportunity RFA-AT-18-002 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications to examine the impact of behavioral interventions within the context of states plans for use of the SAMHSA Opioid STR grant funds authorized under the 21st Century Cures Act. Applications are encouraged for studies that examine the impact of interventions such as mindfulness meditation, cognitive behavioral therapy, or multi-disciplinary rehabilitation for primary or secondary prevention for opioid use disorder (OUD) or as an adjunct to medication assisted treatment (MAT) of OUD. Applications that emphasize treatment of the comorbidity of OUD and chronic pain are of particular interest.

Getting to Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Not Allowed)

Thu, 2017-11-16 09:13
Funding Opportunity PAR-18-411 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve measurement and understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology and novel tools from Big Data science approaches and m/eHealth. The outcome of this research will uncover new knowledge from data to build more effective and context-specific HIV control strategies for the U.S. epidemic.

Notice of Upcoming Webinar for the Strong Heart Study (SHS) - Coordinating Center (CC) Solicitation

Thu, 2017-11-16 03:28
Notice NOT-HL-17-562 from the NIH Guide for Grants and Contracts

NINDS Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)

Wed, 2017-11-15 10:40
Funding Opportunity PA-18-358 from the NIH Guide for Grants and Contracts. The NINDS Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the mission of the NINDS. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community.

Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21 Clinical Trial Optional)

Wed, 2017-11-15 10:29
Funding Opportunity PAR-18-101 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research. Studies should address important clinical and translational questions that are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of prevention, diagnosis or treatment of urologic disorders.

Pilot and Feasibility Clinical Research Grants in Kidney Diseases (R21 Clinical Trial Optional)

Wed, 2017-11-15 10:16
Funding Opportunity PAR-18-100 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment of kidney diseases.

Pages